<DOC>
	<DOCNO>NCT01771848</DOCNO>
	<brief_summary>The study design establish best dose safely infect healthy individual Plasmodium falciparum sporozoite ( PfSPZ ) injection . The goal study achieve infection human volunteer infection rate 100 % pre-patent period less 12 day .</brief_summary>
	<brief_title>Optimization Controlled Human Malarial Infection Injection P. Falciparum Sporozoites Non-Immune Adults</brief_title>
	<detailed_description>This single center , open label , escalate control human pilot study optimize CHMI ( control human malaria infection ) administer PfSPZ Challenge . The study design escalate dose design order answer two question : 1 . Does alter volume administration , alter infectivity PfSPZ Challenge administer IM ( intramuscular ) ? By vary volume inoculation 2,500 dose PfSPZ administer IM try increase infection rate decrease pre-patent period ( Part A ) . 2 . When administered optimum volume determine Part A , increase dose increase infectivity decrease pre-patent period PfSPZ Challenge ? By increase dose PfSPZ try decrease pre-patent period high dose ( Part B ) . Besides increase infectivity rate , aim reduce pre-patent period ~11 day . In Part A trial , volume inoculation vary order identify optimal volume need dose 2,500 PfSPZ induce great infection rate ( define high percentage infect volunteer short pre-patent period . ) The outcome variable part A : 1 . Number volunteer infect per group . 2 . Pre-patent period thick blood smear individual group . 3 . Pre-patent period quantitative PCR ( qPCR ) individual group . 4 . Parasite density parasite first detect thick blood smear qPCR . 5 . Peak parasite density first 48 hour first detection qPCR . During Part A , interim analysis perform order determine optimal volume inoculation use Part B . The variable take account interim analysis : 1 ) number volunteer infect per group 2 ) pre-patent period thick blood smear individual group . Part B ass effect optimal volume inoculation determine part A administer different PfSPZ dos , compare dose 25,000 PfSPZ 50 µL However , ) If optimal volume Part A 10 µL , Group 6 receive 100,000 PfSPZ ( 2 inoculation 50,000 PfSPZ ) instead 125,000 PfSPZ , PfSPZs vialed 100,000 PfSPZ 20 µL . ii ) If optimal volume Part A 50µL , Group 5 modify avoid duplication regimens group 4 5 . In case , volunteer group 5 administer dose 25,000 PfSPZ administer ID ( intradermal ) four 10 µL injection . ( Every volunteer receive 4 ID injection 6,250 PfSPZ volume 10 µL , 2 injection arm respectively ) . The outcome variable part study : 1 . Number volunteer infect per group . 2 . Pre-patent period thick blood smear individual group . 3 . Pre-patent period qPCR individual group . 4 . Parasite density parasite first detect qPCR . 5 . Peak parasite density first 48 hour first detection qPCR . 6 . Estimated number ( ±95 % confidence interval ) liver stage schizonts per volunteer mean ( ±95 % confidence interval ) group . All volunteer recruit healthy adult age 18 45 year . Safety infectivity data collect regimens dose-levels . Volunteers clinical investigator blind group allocation , however laboratory investigator process blood film sample qPCR analysis blind group allocation .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Healthy adult age 18 45 year Able willing ( Investigator 's opinion ) comply study requirement Women : must agree practice continuous effective contraception duration study ( hormonal contraceptive , condom intrauterine device ( IUD ) ) . Agreement refrain blood donation Spain course study thereafter Agree participate another study investigational product course study Written inform consent undergo CHMI Reachable ( 24/7 ) mobile phone whole study period Willingness take curative antimalarial regimen Agreement stay overnight observation period intensive followup postchallenge require Answer question inform consent quiz correctly A body mass index &lt; 35 History P. falciparum malaria Travel malaria endemic region participation study positive P. falciparum serology screen . Use systemic antibiotic know antimalarial activity within 30 day study enrolment ( e.g . trimethoprimsulfamethoxazole , doxycycline , tetracycline , clindamycin , erythromycin , fluoroquinolones , azithromycin ) Is use intend continue use medication know cause drug reaction chloroquine Malarone® , cimetidine , metoclopramide , antacid kaolin ( antacid kaolin administer least 4 hour intake chloroquine ) Receipt investigational product 30 day precede enrolment , plan receipt study period Prior receipt investigational malaria vaccine Any confirm suspected immunosuppressive immunodeficient state , include HIV infection , asplenia , recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) Use immunoglobulins blood product within 3 month prior enrolment Presence sickle cell anemia , sickle cell trait , thalassemia thalassemia trait Pregnancy , lactation intention become pregnant study A history allergic disease reaction likely exacerbate malaria Contraindications known allergy firstline antimalarial medication : chloroquine , atovaquone/proguanil artemether/lumefantrine . History cancer ( except successfully treat cure basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition may affect participation study Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 30g ( men ) 20g ( woman ) per day Suspected known injecting drug abuse 5 year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) An estimate , ten year risk fatal cardiovascular disease ≥5 % , estimate Systematic Coronary Risk Evaluation ( SCORE ) system [ 42 ] Abnormal electrocardiogram screening : pathologic Q wave significant STT wave change , leave ventricular hypertrophy , nonsinus rhythm except isolated premature atrial contraction , right leave bundle branch block , advance AV heart block ( secondary tertiary ) Volunteers unable closely follow social , geographic psychological reason Any clinically significant abnormal find biochemistry haematology blood test , urinalysis clinical examination Any significant disease , disorder finding , opinion Investigator , may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
</DOC>